GLP-1 pills are coming, and they could revolutionize weight-loss
Sep 17, 2024 · Semaglutide in a pill The most advanced of these pills include a form of semaglutide, the active ingredient in Ozempic and Wegovy, being developed by Novo Nordisk.
FDA Approves First Treatment to Reduce Risk of Serious ...
Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults...
New GLP-1 drugs promise weight loss and health benefits - NBC News
The drug combines GLP-1 and glucagon. In a phase 3 study of adults in China who were overweight or had obesity, researchers found that after 48 weeks, a 6-milligram dose of the drug led to an...
As Semaglutide's Popularity Soars, Rare but Serious ...
The recent analysis in JAMA focused on serious stomach disorders and GLP-1 agonists. Researchers in Canada compared safety outcomes for GLP-1 agonists and bupropion-naltrexone, an older class of weight-loss medication.
Weight-loss drug lowers cardiovascular disease risk in new ...
Aug 24, 2023 · Novo Nordisk released results from its SELECT trial on 8 August 2023 showing that patients receiving the GLP-1 analog semaglutide (Wegovy) had a 20% reduction in cardiovascular events compared...
Are GLP-1 drugs really for everybody? | Nature Medicine
1 day ago · In the SELECT trial involving a highly diverse pool of participants, treatment with the GLP-1RA semaglutide resulted in clinically meaningful weight loss over 208 weeks 2.Despite the significant ...
Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists
2 days ago · Discontinuing GLP-1 RA therapy has important clinical implications. In the STEP-1 extension 3 and STEP-4 trials, 4 two-thirds of the weight lost on treatment was regained after discontinuation of semaglutide, with worsening of cardiometabolic parameters such as glucose levels, blood pressure, and cholesterol levels. While the effect of discontinuation on cardiovascular risk is not well-defined ...
FDA approves first oral GLP-1 treatment for type 2 diabetes
The U.S. Food and Drug Administration today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise.
Semaglutide and Cardiovascular Outcomes in Obesity ...
Nov 11, 2023 · Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with ...
Semaglutide offers new route to cardiovascular risk reduction
Nov 30, 2023 · In people with cardiovascular disease (without diabetes) and overweight or obesity, the GLP-1 receptor agonist semaglutide significantly reduced the risk of major cardiovascular events.